In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results